Heart Failure Congress 2024 has unveiled 8 Late-breaking trial sessions for 2024.
Heart Failure 2024 will take place at the Lisbon Congress Center in May. Access the full Programme here.
Late breaking clinical trials I
Saturday 11th May, 08:30 – 09:30am
- Intravenous iron therapy with ferric carboxymaltose results in a rapid and sustained rise in myocardial iron content through a non-canonical pathway: a translational study
- Timing of Cardio-Kidney Protection with SGLT2 Inhibitors: Insights from Four Large-scale Placebo-Controlled Outcome Trials
- Impact of a remote monitoring program on all-cause mortality of patients with heart failure: National, real-world evidence of the TELESAT study
- The consistency of the treatment benefit of remote hemodynamic monitoring in chronic heart failure: a predefined subgroup analysis of the randomised clinical Trial MONITOR-HF
- Suspected de novo heart failure in outpatient care: high mortality and morbidity rates (REVOLUTION HF)
Late breaking clinical trials: medical therapy
Saturday 11th May, 13:45 – 14:45pm
- A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure
- A phase 2, randomized, double-blind, placebo-controlled study to assess the tolerability and pharmacodynamic effects of CRD-740, a PDE9 inhibitor, in participants with chronic heart failure
- Readily available urinary sodium analysis in patients with acute decompensate Heart Failure
- DEA-HF: The heart failure diuresis efficacy comparison study
- Low-dose administration of carperitide for Acute Heart Failure
Late breaking clinical trials: registries
Sunday 12th May, 08:30 – 09:30am
- Cardiovascular burden of the amyloidogenic V1421 transthyretin variant in black individuals
- Incidence and prognosis of respiratory failure in acute heart failure
- Sex-specific clinical outcomes and healthcare resource utilization in the 5 years following hospitalization for heart failure
- Glucagon-like peptide-1 receptor agonist in obese heart failure with preserved ejection fraction and type 2 diabetes mellitus
- Portuguese Heart Failure Prevalence Observational Study
Late breaking clinical trials: devices
Sunday 12th May, 10:45am – 12:15pm
- Correlation of the non-invasive cardiopulmonary management wearable device with measures of congestion in Heart Failure study
- A Prospective, Multi-center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients
- REducing Lung congestIon symptoms using the v-wavE shunt in adVancEd Heart Failure
- Cardiac Resynchronization Therapy DeliveRy Guided by Non-Invasive Electrical and Venous Anatomy Assessment (CRT-DRIVE) Clinical Trial
- Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation
- Low mortality in AdaptResponse compared to historical pharmacological and CRT trials in heart failure with reduced ejection fraction
- Differential effects of inter-atrial shunt treatment on cardiac structure and function in patients with heart failure reduced vs preserved ejection fraction: data from RELIEVE-HF Trial
- Transvenous phrenic nerve stimulation to treat central sleep apnea in heart failure
Late Breaking Clinical trials: drugs and disease management
Sunday 12th May, 13:45 – 14:45pm
- The effect of empagliflozin after acute myocardial infarction in patients with and without diabetes: a pre-specified analysis of the EMPACT-MI trial
- Contemporary guideline-directed medical therapy sequencing and titration in de novo, worsening, and chronic heart failure: first data from the TITRATE-HF study
- First implementation results from the Trial for Evaluating Accelerated Guideline-Directed Medical Therapy for Heart Failure
- Pragmatic Urinary Sodium-based algoritHm in Acute Heart Failure trial
- Efficacy of hypertonic saline therapy in ambulatory patients with heart failure
Late Breaking Clinical trials: further analyses and baseline characteristics
Monday 13th May, 08:30 – 09:30am
- Semaglutide 2.4 mg and NTproBNP in obesity-related HFpEF: insights from the STEP-HFpEF programme
- Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF
- Effect of IV iron in patients with heart failure with preserved ejection fraction
- Design and baseline characteristics of FINE-HEART: an integrated pooled analysis of finerenone in >19,000 participants across 3 phase III trials of HF & CKD
- Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: baseline characteristics of patients in the RESHAPE-HF2 trial
Late Breaking Clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy
Monday 13th May, 13:45 – 14:45pm
- Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial
- Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme
- Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial
- Enhancing exercise response in obstructive HCM: insights from aficamten's impact on patients with obstructive hypertrophic cardiomyopathy in SEQUOIA-HCM
- Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM
Late breaking clinical trials II
Tuesday 14th May, 08:30 – 09:30am
- Transendocardial injection of autologous expanded CD34+ Stem Cells (ProtheraCytes) promotes reverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction
- Bio-ADM as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure; data from STRONG-HF
- Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial
- Cardiac reverse remodeling in the trial of accelerated guideline-directed medical therapy for Heart Failure (TEAM-HF)
- Suspected de novo heart failure in outpatient care: high overall healthcare costs (REVOLUTION HF)